Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 11/20 | 0.39 |
| ▸ | TP53 | P04637 | 8/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4530374 | 1.00 | MPL (0.39) | MPLMAPTTP53LMNATHRB | |
| SCHEMBL4515420 | 0.93 | MPL (0.40) | MPLMAPTTP53LMNATHRB | |
| SCHEMBL4515428 | 0.93 | MPL (0.40) | MPLMAPTTP53LMNATHRB | |
| SCHEMBL4515689 | 0.92 | MPL (0.48) | MPLMAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL4515681 | 0.92 | MPL (0.48) | MPLMAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL4524827 | 0.90 | MAPT (0.41) | MPLMAPTTP53LMNATHRB | |
| SCHEMBL4524822 | 0.90 | MAPT (0.41) | MPLMAPTTP53LMNATHRB | |
| SCHEMBL4499890 | 0.89 | MAPT (0.40) | MPLMAPTTP53LMNATHRB | |
| SCHEMBL4499887 | 0.89 | MAPT (0.40) | MPLMAPTTP53LMNATHRB | |
| SCHEMBL4560412 | 0.88 | MAPT (0.40) | MPLMAPTTP53LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1655291-B1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO (JP) | 2016-08-03 | — | — | EP | disclosed |
| US-20090318513-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. | 2009-12-24 | — | — | US | disclosed |
| US-7601746-B2 | Compounds exhibiting thrombopoietin receptor agonism | SHIONOGI & CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) | 2007-02-22 | — | — | US | disclosed |
| EP-1655291-A1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. (JP) | 2006-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318513-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | MPL, TEK, GHRHR | MPL 1/4885MAPT 4201/4885TP53 1588/4885 |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | DHFR, NAT1, ACR | MPL 3714/4885MAPT 3495/4885TP53 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.